Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research
December 08 2017 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated
nutraceutical company devoted to extending human healthspan,
announced today that in research published in the journal Nature,
Dr. Johan Auwerx showed that Alzheimer’s disease (AD) mice treated
with nicotinamide riboside (NR) had lower levels of amyloid
deposits, improved mitochondrial energy production and improved
memory.
Alzheimer’s disease is a devastating age-related
neurodegenerative condition with no known cure. Identifying early
mechanisms of the disease and approaches to prevent AD are among
the most important priorities of global biomedical research.
Dr. Auwerx and colleagues at the Ecole
Polytechnique Federale de Lausanne in Switzerland, revealed that
people with mild cognitive impairment and Alzheimer’s disease have
characteristic changes in their brain mitochondria. Dr. Auwerx and
colleagues demonstrated that in development of the disease,
mitochondrial energy output is reduced and the mitochondrial stress
response, which normally recycles damaged mitochondrial proteins,
is inactivated. Reasoning that mitochondrial function might be
restored by molecules such as NAD+ that are limiting to energy
production, Dr. Auwerx tested NR, a recently discovered vitamin and
effective NAD+ booster. Dr. Auwerx showed that AD mice treated with
NR had lower degrees of amyloid deposits, improved mitochondrial
energy production and improved memory.
Remarking on Dr. Auwerx’s discovery, Dr. Rudolph
Tanzi, the Vice-Chair of Neurology and Director of the Genetics and
Aging Research Unit at Massachusetts General Hospital, the Joseph
P. and Rose F. Kennedy Professor of Neurology at Harvard Medical
School, and a member of the Scientific Advisory Board of ChromaDex
commented, “We’ve long been fascinated by mitochondrial changes in
AD pathology and have been intrigued with the possibility of a
bioenergetic deficit in AD. Work published today clearly justifies
testing NR in the context of mild cognitive impairment.”
Dr. Charles Brenner, the Roy J. Carver Chair and
Head of Biochemistry at the University of Iowa and the Chief
Scientific Advisor of ChromaDex continued “given the preclinical
data and the human safety data that are coming out, we’re thrilled
to have additional well vetted applications where we can test NR to
improve the human condition. By combining novel imaging modalities
with NAD metabolomics, we expect to see multiple opportunities to
test NR as a neuroprotective agent in people in coming years.”
NR is a vitamin discovered by Dr. Brenner and
developed by ChromaDex.
About ChromaDex:
ChromaDex leverages its complementary
business units to discover, acquire, develop and commercialize
patented and proprietary health and wellness consumer products and
ingredient technologies that promote healthy longevity. In addition
to our consumer product and ingredient technologies units, we also
have business units focused on natural product fine chemicals
(known as "phytochemicals"), and product regulatory and safety
consulting. As a result of our relationships with leading
universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then
utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our
consumer product and ingredient portfolio are backed with clinical
and scientific research, as well as extensive IP protection. Our
portfolio of patented ingredient technologies
includes NIAGEN® nicotinamide
riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina
extract; AnthOrigin®, anthocyanins derived from a
domestically-produced, water-extracted purple corn husk, and
ChromaDex’s flagship consumer product TRU NIAGEN™, found at
truniagen.com. To learn more about ChromaDex, please
visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended including statements related to results of the study and
its significance related to Alzheimer’s disease and the
possibilities as a neuroprotectant. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. Actual results may differ materially
from those set forth in this release due to the risks and
uncertainties inherent in ChromaDex's business. More detailed
information about ChromaDex and the risk factors that may affect
the realization of forward-looking statements is set forth in
ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2016, ChromaDex's Quarter Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ChromaDex undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof.
ChromaDex Investor Relations Contact: Andrew
Johnson, Director of Investor Relations 949-419-0288
andrewj@chromadex.com
ChromaDex Public Relations Contact: Breah
Ostendorf, Director of Marketing 949-537-4103
breaho@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024